




## Transition: preliminary results vs. final official version Q1-3'19



- EBITDA: due positive decision on November 12<sup>th</sup> 2019 of the Brazilian courts with regards to tax liabilities EUR 4.0 m were released from provisions (effective in the segment Sempermed, recognised as a one-off item) – reported figures are adjusted accordingly
- EBIT: Impairment losses at EUR 46.8 m were recognised in the segment Sempermed in Q3'19 due to the significant increase of the competitive environment – thus reported EBIT amounts to EUR -13.7 m, while adjusted EBIT reaches EUR 29.0 m

1) Q1-3'19 EBITDA: Sempertrans positive effects of € 1.3m profit from sale of assets of closed factory in China, and + € 1.7 m insurance claim – reported figures not adjusted